Henoch-Schonlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center

Imagem de Miniatura
Arquivos
art_BUSCATTI_HenochSchonlein_purpura_nephritis_initial_risk_factors_and_outcomes_2018.PDF (385.07 KB)
Citações na Scopus
36
Tipo de produção
article
Data de publicação
2018
Editora
SPRINGER LONDON LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICAL RHEUMATOLOGY, v.37, n.5, p.1319-1324, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The objective of this study was to evaluate prevalence, initial risk factors, and outcomes in Henoch-Schonlein purpura nephritis (HSPN) patients in Latin America. Two hundred ninety-six patients (validated EULAR/PRINTO/PRES HSP criteria) were assessed by demographic data, clinical/laboratorial involvements, and treatments in the first 3 months after diagnosis. They were followed-up in a Latin American tertiary center and were divided in two groups: with and without nephritis. Persistent non-nephrotic proteinuria, nephrotic proteinuria, and acute/chronic kidney injury were also systematically evaluated at 1, 5, 10, and 15 years after diagnosis. HSPN was evidenced in 139/296 (47%) in the first 3 months. The median age at diagnosis was significantly higher in HSPN patients compared without renal involvement [6.6 (1.5-17.7) vs. 5.7 (0.9-13.5) years, p = 0.022]. The frequencies of persistent purpura (31 vs. 10%, p < 0.0001), recurrent abdominal pain (16 vs. 7%, p = 0.011), gastrointestinal bleeding (25 vs. 10%, p < 0.0001), and corticosteroid use (54 vs. 41%, p = 0.023) were significantly higher in the former group. Logistic regression demonstrated that the independent variables associated with HSNP were persistent purpura (OR = 3.601; 95% CI (1.605-8.079); p = 0.002) and gastrointestinal bleeding (OR = 2.991; 95% CI (1.245-7.183); p = 0.014). Further analysis of patients without HSPN in the first 3 months revealed that 29/118 (25%) had persistent non-nephrotic proteinuria and/or hematuria in 1 year, 19/61 (31%) in 5 years, 6/17 (35%) in 10 years and 4/6 (67%) in 15 years after diagnosis. None of them had chronic kidney injury or were submitted to renal replacement therapy. The present study observed HSPN in almost one half of patients in the first months of disease, and HSPN was associated with persistent purpura and gastrointestinal bleeding. One fourth of patients had nephritis only evidenced during follow-up without severe renal manifestations.
Palavras-chave
Children, Corticosteroid, Gastrointestinal bleeding, Henoch-Schonlein purpura, Immunoglobulin a vasculitis, Nephritis
URI
https://observatorio.fm.usp.br/handle/OPI/27014
Referências
  1. Akcan-Arikan A, 2007, KIDNEY INT, V71, P1028, DOI 10.1038/sj.ki.5002231
  2. Anil M, 2009, TURKISH J PEDIATR, V51, P429
  3. Butani L, 2007, CLIN PEDIATR, V46, P505, DOI 10.1177/0009922806298896
  4. Calvino MC, 2001, MEDICINE, V80, P279, DOI 10.1097/00005792-200109000-00001
  5. Cattran DC, 2009, KIDNEY INT, V76, P534, DOI 10.1038/ki.2009.243
  6. Chan H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167346
  7. Chan James C M, 2002, Pediatr Rev, V23, P47, DOI 10.1542/pir.23-2-47
  8. Chen JY, 2015, WORLD J PEDIATR, V11, P29, DOI 10.1007/s12519-014-0534-5
  9. Coppo R, 2006, AM J KIDNEY DIS, V47, P993, DOI 10.1053/j.ajkd.2006.02.178
  10. de Almeida JLJ, 2007, J PEDIAT, V83, P259, DOI [10.2223/JPED.1638, 10.1590/S0021-75572007000400012]
  11. Elmas AT, 2016, J CLIN LAB ANAL, V30, P71, DOI 10.1002/jcla.21817
  12. Feng D, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0146-4
  13. GOLDSTEIN AR, 1992, LANCET, V339, P280, DOI 10.1016/0140-6736(92)91341-5
  14. Ha TS, 2007, ACTA PAEDIATR, V96, P552, DOI 10.1111/j.1651-2227.2006.00173.x
  15. Hetland LE, 2017, ACTA DERM-VENEREOL, V2017, P27
  16. Jauhola O, 2010, ARCH DIS CHILD, V95, P871, DOI 10.1136/adc.2009.167874
  17. Kim CH, 2014, MODERN PATHOL, V27, P972, DOI 10.1038/modpathol.2013.222
  18. Kiryluk K, 2011, KIDNEY INT, V80, P79, DOI 10.1038/ki.2011.16
  19. Mao YY, 2014, J INT MED RES, V42, P1043, DOI 10.1177/0300060514530879
  20. MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114
  21. Modi S, 2016, UROL CASE REP, V6, P9, DOI 10.1016/j.eucr.2016.01.004
  22. Narchi H, 2005, ARCH DIS CHILD, V90, P916, DOI 10.1136/adc.2005.074641
  23. National Kidney Foundation, 2002, AM J KIDNEY DIS, V39, pS1, DOI 10.1016/S0272-6386(02)70081-4]
  24. Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555
  25. Nickavar A, 2012, IRAN J KIDNEY DIS, V6, P437
  26. Ozen S, 2017, CURR OPIN RHEUMATOL, V29, P530, DOI 10.1097/BOR.0000000000000424
  27. Ozen S, 2010, ANN RHEUM DIS, V69, P798, DOI 10.1136/ard.2009.116657
  28. Pacheva IH, 2017, CASE REP PEDIAT, DOI 10.1155/2017/5483543
  29. Rabelo C, 2008, ACTA REUMATOL PORT, V33, P452
  30. Ronkainen J, 2002, LANCET, V360, P666, DOI 10.1016/S0140-6736(02)09835-5
  31. Sano H, 2002, EUR J PEDIATR, V161, P196, DOI 10.1007/s00431-002-0922-z
  32. Shin JI, 2006, SCAND J RHEUMATOL, V35, P56, DOI 10.1080/03009740510026841
  33. Soylemezoglu O, 2009, NEPHRON CLIN PRACT, V112, pC199, DOI 10.1159/000218109
  34. Suehiro RM, 2007, TURKISH J PEDIATR, V49, P189
  35. Terreri MT, 2013, REV BRAS REUMATOL, V53, P346, DOI 10.1590/S0482-50042013000400006
  36. Tudorache E, 2015, ACTA PAEDIATR, V104, P843, DOI 10.1111/apa.12723
  37. Wang XH, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0080-x
  38. Zhao YL, 2015, EUR J PEDIATR, V174, P1357, DOI 10.1007/s00431-015-2547-z

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/29
Carregar mais